Morgan Stanley Cardiff Oncology, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 310,659 shares of CRDF stock, worth $667,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

310,659

Previous 795,746 60.96%

Holding current value

$667,916

Previous $2.51 Million 74.98%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.96 - $4.51 $950,770 - $2.19 Million	-485,087 Reduced 60.96%	310,659 $627,000
Q2 2025 Aug 15, 2025	BUY	$2.38 - $4.3 $231,378 - $418,037	97,218 Added 13.92%	795,746 $2.51 Million
Q1 2025 May 15, 2025	BUY	$3.14 - $4.75 $490,276 - $741,660	156,139 Added 28.79%	698,528 $2.19 Million
Q4 2024 Feb 14, 2025	BUY	$2.31 - $5.35 $102,210 - $236,721	44,247 Added 8.88%	542,389 $2.35 Million
Q3 2024 May 14, 2025	SELL	$2.05 - $2.77 $30,918 - $41,777	-15,082 Reduced 2.94%	498,142 $1.33 Million
Q3 2024 Nov 14, 2024	SELL	$2.05 - $2.77 $30,918 - $41,777	-15,082 Reduced 2.94%	498,142 $1.33 Million
Q2 2024 May 14, 2025	SELL	$2.22 - $5.89 $64,746 - $171,781	-29,165 Reduced 5.38%	513,224 $1.14 Million
Q2 2024 Oct 17, 2024	BUY	$2.22 - $5.89 $963,033 - $2.56 Million	433,799 Added 546.17%	513,224 $1.14 Million
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $963,033 - $2.56 Million	433,799 Added 546.17%	513,224 $1.14 Million
Q1 2024 Oct 17, 2024	SELL	$1.46 - $5.91 $633,346 - $2.56 Million	-433,799 Reduced 84.52%	79,425 $424,000
Q1 2024 Aug 16, 2024	BUY	$1.46 - $5.91 $93,710 - $379,333	64,185 Added 421.16%	79,425 $424,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $93,710 - $379,333	64,185 Added 421.16%	79,425 $424,000
Q4 2023 Aug 16, 2024	SELL	$0.96 - $1.55 $478,064 - $771,875	-497,984 Reduced 97.03%	15,240 $22,000
Q4 2023 Feb 13, 2024	SELL	$0.96 - $1.55 $3,609 - $5,828	-3,760 Reduced 19.79%	15,240 $22,000
Q3 2023 Nov 15, 2023	BUY	$1.38 - $2.18 $4,536 - $7,165	3,287 Added 20.92%	19,000 $26,000
Q2 2023 Aug 14, 2023	SELL	$1.37 - $1.95 $257,744 - $366,863	-188,135 Reduced 92.29%	15,713 $23,000
Q1 2023 May 15, 2023	SELL	$1.45 - $2.09 $111,531 - $160,758	-76,918 Reduced 27.4%	203,848 $336,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $117,083 - $159,310	-95,970 Reduced 25.47%	280,766 $393,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $20,046 - $41,784	13,017 Added 3.58%	376,736 $580,000
Q2 2022 Oct 27, 2022	BUY	$1.17 - $2.61 $178,150 - $397,411	152,265 Added 72.01%	363,719 $800,000
Q2 2022 Aug 15, 2022	BUY	$1.17 - $2.61 $178,150 - $397,411	152,265 Added 72.01%	363,719 $800,000
Q1 2022 Oct 27, 2022	SELL	$2.11 - $7.25 $321,279 - $1.1 Million	-152,265 Reduced 41.86%	211,454 $524,000
Q1 2022 May 13, 2022	SELL	$2.11 - $7.25 $716,387 - $2.46 Million	-339,520 Reduced 61.62%	211,454 $524,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $2.29 Million - $3.21 Million	442,874 Added 409.69%	550,974 $3.31 Million
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $541,581 - $819,398	108,100 New	108,100 $719,000

Others Institutions Holding CRDF

# of Institutions

124

Shares Held

21.8M

Call Options Held

1.11M

Put Options Held

150K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $93.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account